How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC
How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 31, 2023
Expiration Date: March 31, 2024
Description:
This online, on-demand virtual symposium brings together renowned experts in tissue stewardship and testing of tumor specimens to detect NTRK or RET gene fusions, ALK or ROS1 gene rearrangements, the development of on-target resistance mutations in TKI-treated tumors and the management of patients with somatic mutation-driven non–small cell lung cancer (NSCLC). In this educational program, these experts use both educational presentations and a case-based format to discuss the latest data regarding management of emerging mutations and treatments in NSCLC.
This educational activity is an archive of the live independent satellite symposium held on March 15, 2023, adjacent to USCAP 2023.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Outline recent approaches for biomarker testing to detect oncogenic rearrangements and gene fusions in patients with advanced non–small cell lung cancer (NSCLC)
• Determine approaches to integrate biomarker testing based on expert recommendations and recent guidelines to identify patients with NSCLC with oncogenic gene fusions that would benefit from targeted therapies
• Describe clinical trial evidence concerning the role of biomarker-directed therapies in patients with NSCLC and actionable biomarkers including NTRK- and RET-fusions, as well as ALK- and ROS-rearrangements
• Explain the rationale for novel approaches targeting NRG1 fusion in NSCLC and testing approaches for identifying patients with NRG1 fusion-positive NSCLC